OIS Index Outperforms

OIS Index Outperforms

The OIS Index of ophthalmic stocks gained 5.4% in November, following a similar 5.2% gain in October. The index outperformed medical device stocks (+4.3%) and the broader US stock market (+3.6%) but lagged the biotech sector (+11.4%).

The largest positive contributor was Adverum Biotechnologies (+50.1%), which continued its steady rebound from a September decline related to the company’s Phase 1 gene therapy study in wet AMD. The largest percentage gainer was Eyenovia (+53.8%), which moved higher following the company’s Q3 financial report and business update.

Other ophthalmic stocks that participated in the November biotech rally included Aldeyra Therapeutics (+42.8%), KalVista Pharmaceuticals (+36.6%), MeiraGTx (+33.4%), and Alimera Sciences (+33.2%). Two of the large diversified ophthalmic device companies, Bausch Health (+13.7%) and Carl Zeiss Meditec (+12.9%), also contributed significantly to index performance.

SHARE THIS ARTICLE WITH YOUR COLLEAGUES:

RECOMMENDED FOR YOU

The Strategy Behind EyeGate’s Acquisition of Panoptes 3

The Strategy Behind EyeGate’s Acquisition of Panoptes

Lessons learned for Conducting Clinical Trials in Challenging Times

Lessons learned for Conducting Clinical Trials in Challenging Times

Looking Ahead to 2021, Finding Value in 2020’s Lessons

Looking Ahead to 2021, Finding Value in 2020’s Lessons

Novartis Steps Up Digital Strategy for AMD Treatments and Patient Support - Web

Novartis Steps Up Digital Strategy for AMD Treatments and Patient Support

800-pound Gorilla Doesn’t Deter Investors in Ophthalmology Sector 2

800-pound Gorilla Doesn’t Deter Investors in Ophthalmology Sector

With Hemera Deal Janssen Continues Building Out Its Retina Portfolio Glaucoma on the Horizon _ Social

With Hemera Deal, Janssen Continues Building Out Its Retina Portfolio: Glaucoma on the Horizon

About The Author

Michael Lachman

Michael Lachman is President of EyeQ Research, which provides market research, analytics, and strategic advisory to ophthalmic companies and investors. Previously, he was a healthcare investment research analyst with Hambrecht & Quist, ThinkEquity Partners, and SAC Capital, and worked in business development, marketing, and R&D for Johnson & Johnson and Baxter.

SUBSCRIBE TO OUR NEWSLETTER

Get The Latest News In Opthalmologic Innovation To Your Inbox.

We respect your privacy and will never send you spam.

Something went wrong. Please check your entries and try again.

SUBSCRIBE TO OIS WEEKLY

Get our monthly newsletter about the latest in opthalmologic innovation.

We respect your privacy and will never send you spam.

Something went wrong. Please check your entries and try again.

STAY CONNECTED

NEW VIDEOS

PODCASTS